Product Pipeline

Programs
TASC
Signal

U3 Pharma is committed to developing innovative products designed to safely and effectively treat patients with cancer and improve patient outcomes.

We are focusing our resources on developing four biopharmaceutical products that are the result of the application of our translational medicine and drug discovery expertise to drug targets identified and validated by U3 Pharma´s founder Prof. Axel Ullrich.

 

Product Description Product Type Status
U3-1287 Receptor tyrosine kinase Human antibody Preclinical
U3-1565 Receptor tyrosine kinase ligand Human antibody Preclinical
U3-1900 Ion channel Humanized antibody Preclinical
U3-1800 Receptor tyrosine kinase Humanized antibody Preclinical
U3-1784 Receptor tyrosine kinase Antibody Research
U3-2000 Intracellular kinase   Research
U3-1299 Intracellular kinase   Research

U3 Pharma AG – Leading programs

U3-1287
The target of U3-1287 is a membrane-bound receptor tyrosine kinase (RTK) that controls a specific signal transduction pathway and has shown involvement in multiple cancer types of epithelial origin, including breast, lung and colorectal cancers, among others. Partnered with Abgenix, now Amgen, U3 Pharma is advancing fully human therapeutic antibodies against this target. U3-1287 is anticipated to enter clinical evaluation in 2007.

U3-1565
The target of U3-1565 is a membrane-bound receptor tyrosine kinase ligand (RTKL), which is a key component of a molecular pathway, discovered and elucidated by Prof. Ullrich, involved in autocrine growth stimulation. U3 Pharma has demonstrated a pivotal role for U3-1565 in multiple cancer types of epithelial origin and has developed fully human therapeutic antibodies against the target under the company´s collaboration with Abgenix, now Amgen. The lead antibodies for this program are anticipated to enter the clinic in 2007.

U3-1900
The target of U3-1900 is an ion channel with oncogenic activity. Discovered in The Max Planck Institute by Prof. Walter Stühmer and Dr. Luis Pardo, the U3-1900 target displays a unique expression pattern identifying it as a tumor marker and target of therapeutic relevance. U3 Pharma has shown that U3-1900 is an effective inhibitor of tumor cell proliferation in vitro and in vivo.

U3-1800
The target of the U3-1800 antibody is a membrane-bound receptor tyrosine kinase whose function had remained unknown until discovered by U3 Pharma and Prof. Axel Ullrich. The target plays an important role in cell migration and invasion in many common types of cancer. U3 Pharma has shown that U3-1800 is an effective inhibitor of tumor cell invasion and migration in vitro and tumor growth in vivo.



Leave a Reply

Your email address will not be published. Required fields are marked *